Asymptomatic
symptoms 
Presymptomatic
infected
Coronavirus
viruses
virus
coronaviruses
SARS
COVID-19
spread
virus
sick
Ventilator
breathe
Pathogen
microorganism
infection
Patient
masks
contagious
Social distancing
Self-isolation
quarantine
Self-quarantine
Shelter
emergency
medicine
spreader
Chronic health
Flatten the curve
hospitals
immune system
diseases
Outbreak
Epidemic
Widespread
Pandemic
Surgical mask
N95
protective
particles
disease 
Herd immunity
immunity
inactive
immune
vaccine
COVID-19
COVID
pandemic
diseases
disease
coronaviruses
Coronavirus
Transmission
SARS-CoV-2
Infectious
Symptoms
Fever
cough
fatigue
shortness of breath
vomiting
loss of taste or smell
asymptomatic
Complications
Pneumonia
viral sepsis
respiratory distress
kidney failure
cytokine release syndrome
respiratory failure
pulmonary fibrosis
pediatric multisystem inflammatory syndrome
syndrome
Causes
acute respiratory syndrome
coronavirus 2
rRT-PCR
CT scan
Face coverings
quarantine
physical distancing
social distancing
ventilation
hand washing
vaccination
vaccine
severe COVID-19 infection
symptomatic COVID‑19 infections
COVID-19 Infection
COVID-19 infections
COVID-19 infection
COVID-19 disease reinfection
COVID-19 Virus
COVID-19 virus
covid-19 infection
COVID-19 disease severity
COVID-19 Outbreak
Covid-19 disease
COVID-19 infection prevention
COVID-19 epidemic
COVID-19 symptoms
COVID-19 Pandemic
COVID-19 pandemic
COVID-19 prevalence
COVID-19 vaccine
several COVID‑19 vaccines
COVID-19 pneumonia
COVID‑19 pandemic
severe COVID-19 patients
chronic COVID syndrome
earlier COVID-19 infection
Covid-19 vaccine
COVID-19 therapeutics
contagious COVID-19 variant
asymptomatic COVID infections
novel coronavirus diseases
COVID‑19 vaccine
COVID-19 Pneumonia
COVID-19 patients
COVID-19 pathogenesis
severe COVID-19
COVID-19 infection fatality rates
pandemia por COVID-19
COVID-19 vaccines
COVID-19 Patients
COVID virus
lab-confirmed SARS-CoV-2 infection
most COVID-19 vaccine
COVID-19 deaths
co-infections
COVID-19 cases
covid-19 vaccines
Novel Coronavirus Diseases
ill COVID-19 patients
SARS-CoV-2 Infection
Severe Acute Respiratory Syndrome Coronavirus
coronavirus disease
contagious disease
Coronavirus disease
Coronavirus diseases
severe COVID‑19
COVID-19 pandemic death rates
Severe acute respiratory syndrome coronavirus
SARS-CoV-2 Infections
COVID-19-related
COVID-19 Autopsy Cases
COVID-19 pathophysiology
SARS-CoV-2 infection
severe acute respiratory syndrome coronavirus
Covid-19 treatments
pediatric multisystem inflammatory syndrome
COVID-19
COVID-19 treatment
infectious SARS-CoV-2 virions
novel coronavirus outbreak
Laboratory-Confirmed Coronavirus Disease
COVID‑19
Coronavirus Disease
COVID-19 vaccine authorizations
presymptomatic SARS-CoV-2 infections
SARS-CoV-2 virus
Asymptomatic SARS-CoV-2 Infection
COVID-19 treatments
Infectious disease
Covid-19
COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy
COVID-19 testing
COVID-19-Immunopathological Mechanisms
COVID-19 Vaccine Rollout
non-severe COVID-19
COVID-19 drug
COVID-19 misinformation
COVID-19 pandemic response
novel coronavirus pneumonia
COVID-19 apps
moderate COVID‑19
life-threatening COVID-19
COVID-19 NOS
first COVID-19 vaccine
COVID-19 case
novel coronavirus cases
contagious coronavirus variant
COVID-19
CoV-2 virus
critical COVID-19
coronavirus cases
coronavirus complications
vaccination
COVID-19 drug development
COVID-19 people
viral illnesses
Infectious Severe Acute Respiratory Syndrome Coronavirus
Severe acute respiratory syndrome coronavirus-2
COVID-19Occupational safety
Novel Coronavirus
mild-to-moderate COVID-19
many effective COVID-19 vaccines
other infections such
Novel Coronavirus-Infected Pneumonia
coronavirus infection
Coronavirus Cases
Covid-19 Pathogenesis
COVID-19 case fatality
lung diseases
COVID-19 research
pathogenic human coronavirus infections
virus
ill COVID-19 patients
official names COVID-19
Novel coronavirus
COVID-19 survivors
novel coronavirus
severe disease infection
post-COVID syndrome assessment clinics
CanSinoBIO COVID-19 vaccine
corona virus disease
Infectious diseases
infections
Virus
Clinical Infectious Diseases
COVID-19 transmission
other similar viruses
other diseases
Coronavirus vaccine development
COVID-19 Therapies
infectious virus
Sida-aids.png Viruses portal
COVID-19 health outcomes
novel severe acute respiratory syndrome coronavirus
SARS-COV2 virus targets
Multisystem inflammatory syndrome
patients post-infection
infection
Early COVID-19
Novel Coronavirus
coronavirus
COVID-19 Vaccine Deferred Dose
asymptomatic infections
coronavirus genomes
active COVID-19
virus names
Virus Variant
COVID-19 vaccine development pipeline
coronavirus deaths
Host-Virus Interaction
virus strain
COVID-19 ARDS
infection-fatality risk
other viruses
typical pre-COVID-19 ARDS
coronavirus pandemic
recovery—named long COVID—and damage
respiratory problems
Wuhan Coronavirus
COVID-19 antibody therapeutics tracker
COVID-19 case fatality rates
healthViral respiratory tract infectionsZoonosesPublic health
long-term pulmonary consequences
Coronavirus
infected person coughs
COVID-19 surveillance
SARS-CoV-2 cytokine storm
Infectious Diseases
pneumonia-associated respiratory syndrome
virus responsible
COVID vaccines
COVID-19 Treatment Guidelines
severe acute respiratory syndrome
New COVID-19 Variants
Oxford Clinical Infectious Diseases
coronavirus patients
virus infection
virus
COVID-19 Treatment Authorized
viral systemic diseases
critical diseases
COVID-19
COVID19
direct SARS-CoV-2 viral testing
COVID Symptom Study
coronavirus stigma
Different vaccine candidate types
Treatment Coronavirus
symptoms
influenza
SARS–coronavirus
vaccine
disease transmission
Novel Coronavirus Pneumonia Emergency Response Epidemiology Team
viruses
COVID-19 Resource Directory
positive SARS-CoV-2 RNA
BNT162b2 mRNA Covid-19 Vaccine
respiratory symptoms
Wuhan coronavirus deaths
undiagnosed infections
SARS-CoV-2 patients
adenovirus
antiviral drugs
various vaccine technologies
Virus proteins
harmless virus particles
National COVID-19 Clinical Evidence Taskforce
Novel Coronavirus Information Center
coronavirus weeks
novel SARS-CoV-2 virus particle
COVID-19
covid-19 crisis
paediatric multisystem inflammatory syndrome
anti-HIV drugs
many diseases
severe disease
vaccines
COVID-19 Resource Centre
New Human Infectious Diseases
Symptoms
virus-host range
severe illness
acute respiratory illness cases
lab-confirmed SARS-CoV-2
coronavirus misinformation
pneumonia case numbers
COVID-19 Presents Significant Risks
influenza type
diabetes mellitus
mild-to-moderate COVID-19
other coronary artery disease issues
Complications
novel virus
Infectious Diseases Society
pneumonia outbreak
infection fatality
COVID-19 datasets
coronavirus increase
WHO/2019-nCoV
acute respiratory distress syndrome
Long COVID
long COVID
SARS-CoV-2 detection
1st U.S. virus death
age-specific infection rates
clinical illness
Other infected people
Chronic Disease
COVID
virus replication
Respiratory Diseases
viral vector vaccines
prevalence
COVID-19 Informational Resources
COVID-19 advice
JHMI Clinical Recommendations
WIBP-CorV
variant VUI-202012/01
Long-term symptoms
infectivity
antiviral remdesivir
vaccine development
Dire COVID Cases
Lancet Infectious Diseases
serious symptoms
Molecular immune pathogenesis
prevention research
Neurological complications
steroid-refractory cytokine release syndrome
clinical features
critical disease
Pathogens
critical symptoms
disease
virus transmission indoors
severe symptoms
Diagnosis
Covid19
pathogenic GM-CSF
Cardiac Infection
disease codes U07.1
Non-pharmaceutical interventions
syndromes
such infections
mRNA Vaccines
epidemiological characteristics
pulmonary fibrosis
severe disease
promising coronavirus treatments
coronavirus structure
digestive symptoms
cytokine release syndrome
Non-pharmaceutical intervention
Diagnostic Samples
subgenus Sarbecovirus
pathogens
SARSr-CoV virion
Studies Show N.Y. Outbreak
Longer-term effects
other bat coronavirus samples
critical illness
initial outbreak
infection fatality rate
infection
SARS-CoV-2
coronavirus info
SARS-CoV-2 genetic sequence data
prognosis
COVID-19 Database
Pfizer Coronavirus Vaccine
live virus tests
Clinical Characteristics
infection fatality ratio
syndrome
other common upper respiratory diseases such
acute respiratory disease
Ischemic Heart Disease
symptoms similar
SARS-like virus
Pandemic prevention
stringent CDC criteria
cell-mediated immunity
Clinical features
cardiovascular symptoms
antimicrobial resistance
multi-organ injuries
complications
COVID-NET
Mystery pneumonia virus
infected individuals
human infections
infection fatality rates
coronavirus death
lung disease
neurological manifestations
noticeable symptoms
vaccine candidates
Host cytokine response
clinical characteristics
convalescent serum administration
neurological issues
infectious aerosols
Treatment-related research
diseases
immunotherapeutics
SARS-CoV-2 genomes
respiratory failure
symptoms
Coronavirus Resource Center
tentative SARS-CoV-2 therapeutics
Antimicrobial Resistance
infected people
Cytokine release syndrome
other symptoms
Disinfection Processes
Clinical characteristics
cytokine storm syndromes
future SARS-related CoV
Hospital Infection
obstetric complications
SARS-CoV-2 RNA testing
COVID Drugs
antiviral drug therapies
critical respiratory comorbidities
mild symptoms
Middle East respiratory syndrome
elevated C-reactive protein
Vaccinations
Critically Ill Patients
different symptoms
respiratory symptom cluster
protein subunit vaccines
cases
Coronavirus recovery
spillover
epidemic threat
RNA vaccines
SARS‑CoV‑2
moderate symptoms
COVID 19-Induced Smell
new coronavirus
chronic condition such
disease progression
manifestations
patients
China coronavirus
Epidemiological Characteristics
Vision Medicals
Viral testing
diagnosis
Infection Fatality Rate
Cardiovascular complications
severe cases
Moderate Covid-19
C-reactive protein levels
Covid-19 Origin
mild disease
antiviral activity
pathogenic GM-CSF-secreting
immunosuppression
Clinical Virology
infected person
Long Term Health Effects
new coronavirus antibody test
cure
viral replication process
anti-GM-CSF monoclonal antibody
multi-organ failure
Passive antibodies
Potential Fecal-Oral Transmission
immune system disorders
Enfermedades Digestivas
Common symptoms
SARS-CoV-2 variants
SARS-CoV-2
protocols
diffuse alveolar exudates
outbreak
infected wearers
epidemiology
noticeable symptoms
interventions
acute respiratory
Vaccines
other public health measures
macrophage inflammatory protein 1‑alpha
Spanish flu
rRT-PCR testing
medications
antiviral drug promises
high clinical suspicion
incidence
Interim Laboratory Biosafety Guidelines
infection rate
efficacy
Usual onset
Virological characterization
respiratory hygiene
deaths due
life-cycle
Covid
SARS-CoV-2 Variant VOC 202012/01
Infection fatality rate
Corticosteroids/2020.1
Lab Biosafety Guidelines
severity
Clinical Questions
infection
paediatric patients
broad-neutralizing antibodies
Pandemic
other clinical studies
Middle East Respiratory Syndrome
incidences
Olfactory Dysfunction
Coronavirus Kills Mink
epidemiologic data
immune therapies
virological characterization
Disease Control
SARS-CoV-2 transmission
inflammatory infiltrates
reinfection
infection control actions
Infection
many health conditions
moderate cases
Pneumonia
Coronavirus Origin
Medical journals
vaccination
viral pneumonia
new coronavirus
Infectious Hazards
Clinical predictors
main pathological findings
epidemics
Tobacco Induced Diseases
pandemic
Comorbidities
Cuidados
pneumonia
interstitial inflammation
Microvascular Injury
widespread transmission
possible pathophysiology
New Coronavirus gene sequencing
Kawasaki disease
classical serum biomarkers
ICD-10
Hematology Laboratory Abnormalities
Human Vaccines
viral sepsis
other manifestations
Emerging SARS-CoV-2 Variants
cell-induced CRS
common drugs
vaccine doses
therapeutics/2020.1
antibody-dependent cellular cytotoxicity
other prophylactic measures
population-wide interventions
SARS-CoV-2 Transmission
Reinfection
Available Pharmacologic Therapies
serious long-term effects
pulmonary embolisms
interferon-inducible protein
Chronic Conditions
Prognosis
hyperimmune immunoglobulin
global health concern
pulmonary oedema
Same-Hospital Readmission
prevention
milder symptoms
Viral
Kidney Transplant Recipients
pro-inflammatory cytokines
other nucleic acid testing
anti-malarial drugs chloroquine
VOC 202012/01
COVID-19 weekly surveillance report
ongoing pandemic
infected surfaces
transmission
same infection
hard respiratory infections
Epidemiology
receptor blocker medications
mild cases
Testing Clinical Specimens
early infection
Phase I–II trials
clinical readouts
cureus.9438
passive antibodies
Vaccine
long-lasting effects
Prevention
hepatitis
co-morbid conditions such
possible drug targets
other coronaviruses
Diseases
disinfection procedures
Medical response
methamphetamines
human-to-human transmission
Pharmacologic Treatments
Disease Control Prevention
Pathophysiology
severe illness
Infectivity
pathophysiology
second infection
diabetes
Human-to-human transmission
Clinical Immunology
SARS virus receptor
tumour necrosis factor
digestive symptoms
alveolar disease
clinical studies
International research
long-term problems
clinical research
Virology
Immunotherapeutics
drugs
non-vaccine method
TB-related deaths
nucleic acid tests
special control measures
symptom onset
medicines
chemokines
consequences
smaller infected droplets
Diagnostic method
non-smokers
health risk
convalescence
disinfection
U.S. CDC
anti-inflammatory agents
severe symptoms
Medicines
pathogenesis
Several vaccines
GM-CSF inhibition
Laboratory diagnosis
Disease
genus Betacoronavirus
human cases
convalescent serum
LCCN
Interim Clinical Guidance
aerosol-generating medical procedures
unconstrained outbreak
pneumonia cluster
Wuhan pneumonia
bat-derived strains
throat disorders
large atypical pneumocytes
International response
CDC
Immunopathology
systemic hyperinflammation
Clinical laboratory findings
Asymptomatic
Patients
new infection
immune systems
pandemic containment measures
causes
Brazil Infected Many
Disease Prevention
symptom
Metabolic Syndrome
Follow-up study
clinical trials
severe disease
interleukin-6 receptor antagonist
novel coronaviruses
ICU
inflammation
pulmonary function
Cytokine storm
cat-to-human transmission
hypertension
Other Coronaviruses
Myocardial infarction
Mild cases
heart disease
coughs
kidney failure
vaccine tracker
milder cases
inflammatory IL-6-secreting monocytes
quarantine
Proposed Neurotropic Mechanisms
company Vision Medicals
outcomes
variants
infected animals
severe lung pathology
Molecular Immunology
WikinewsDefinitions
Presymptomatic
SARS-CoV2
complication
Signs
several risk factors
long-term effects
mortality due
Viral Load Exposure Factors
more severe cases
HIV
respiratory droplets
Research Highlights
related coronaviruses
VItamin
interferon-α effector genes
tuberculosis
progression
Ncip Epidemic Response
microvascular blood vessel damage
Chest X-ray
kidney transplant recipients
Pathogenesis
Clinical Research
RT-PCR Testing
rare cases
global pharmaceutical industry
diffuse alveolar damage
chronic damage
so-called P.1 variant show
WHO-China Joint Mission
opioids
Ventilation
interleukin-6 receptor antagonist tocilizumab
low prevalence
immunity
dodgy cures
Microbiology
COVID-19 Employer Information
hospital readmissions
chronic renal failure
Infected people
D000086382SNOMED
Cytokine Storm
Other names
immune system
RT-PCR testing
Diabetes
granulocyte-macrophage colony-stimulating factor
relevant hospital authorities
hypertensive patients
cytokine
additional cases
age-specific IFRs
pericarditis
several testing protocols
Viral targets
procedures
convalescent sera option
antimicrobial activity
Undiagnosed pneumonia
serious illness
susceptibility
unresolved clinical case
IgA antibody levels
Health guidelines
microvesicular
dental clinics
vasculitis
Public Health Emergency
respiratory route
RT-PCR
Most cases
severe hypoxemia.[94
musculoskeletal symptom cluster
cough liquids
variant
mental health issues
high incidence
Transmission
obesity
Sex-based immunological differences
evidence
person-to-person transmission
Wuhan Jianghan CDC
dyspnea
myocardial infarction
deaths
viral protein responsible
good respiratory hygiene
multiple organ injuries
monoclonal antibody-based therapies
Clinical Considerations
Corticosteroids
clinical trial
other aspects
Prevalence
detectable type
Health agencies
health-care services
coronaviruses
rapid progression stage
cytokine storm
epidemic peak
flu
effective treatment
facility such
WHO Scientific
mild pneumonia
Chinese CDC
Deaths
premature delivery
Potential Drug Interaction
RAS inhibitors-lessons
ICU stays
intensive care
Susceptibility
different studies
intravascular coagulation
vitamin
risk
Adolescent Health
medication
mitigation
immune response
diarrhea
past infection
fever
Angiotensin receptor blockers
pulmonary interstitial
contamination
Bamlanivimab
cytokine storm syndrome
sh2020000570
Medical Virology
effects
radiographic findings
chances
investigation
pre-symptomatic individuals
minor fibrin
Clinical Investigation
ACE2 deficiency
laboratories
false positives
global health
mass vaccination campaigns
immunological response
Convidecia
different immunological reaction
angiotensin receptor blockers
positives
concentrated antibodies
Obesity
vomiting
laboratory testing
enzyme angiotensin-converting enzyme
cough
global pandemic
severe cases.[23
recurrent mutations
SARS-CoV-2 clades
Outbreak
recombinant angiotensin-converting enzyme
conditions
control measures
immunization working group
gendered impacts
Biological factors
effective treatments
respiratory tract
treatment effects
early studies
signs
physiological characteristics
Human antibody response
first symptoms
ICU
relative incidence
corticosteroids
epidemic curve
NIH study
show lung abnormalities
risk factor
Asymptomatic carrier state
vital organs.[189][190][191
high-risk groups.[159
hospitalization requirements
host factors
retrospective case studies
characteristics
WikivoyageNews stories
international guidelines
reverse transcription polymerase chain reaction
Misinformation
CommonsSpecies directories
later research
CRS
Public Health England
Various therapeutic strategies
important controversial risk factors
viral RNA fragments.[109
ventilation
scientific reviews smokers
lesions
Several experimental treatments
monocyte chemoattractant protein
remdesivir
underlying immunopathology.[85
pangolin SARS-CoV
enzyme
prior samples
efficacy
pathogen
grave consequences
supportive care
Ultraviolet germicidal irradiation
antimalarial drugs hydroxychloroquine
CoviVac
detection
surgical masks
SARS-CoV
conditions such
asymptomatic carriers
acute hyperinflammatory response
promising drugs
prothrombin time
treatment guidelines
IL‑6
severe immune response
common comorbidities
many researchers
respiratory samples
multiorgan dysfunction).[14
national health
preliminary results
IHR Emergency Committee
liver enzymes
Cases
different cause
areas such
positive results
so-called early treatment.[203][204
s41419
Coronaviruses
trials
Primi due casi
decongestants
medication such
healthcare system quality
inocuylum volumes
IFNs
cause
NCIRD
healthcare settings
misinformation
CC-BY icon.svg
imaging findings
NIOSH-certified N95
recommendations
neuroinvasive potential
Epidemiology Working Group
lymphocytic infiltration
mask
Phase III Clinical Trial
Quarantine
hypoxia
Systemic Corticosteroids
non-medical face coverings
Variants
Workplace hazard controls
primary care
U.K.
common precaution
oxygen support
variety
fatality cases
Gastrointestinal Manifestations
Effective treatment
serum IL-6 levels
antibodies
venous thromboembolism
lymphopenia
Hygiene
months
Several measures
clinics
rRT-PCR
Several other types
confirmation
encephalitis
various medical institutions
acute encephalopathy
single dose interim use
prolonged period such
laboratory
Genetic screening
secretion
Potential interventions
chemicals
coagulation factors
other projects
olfactory bulbs
drug
morbidity
pulmonary oedema
Ongoing Investigation
N95 respirator masks
country-based mitigation measures influence
Specialty
Microbes
fatigue
Cumulative
cystic
wellness
Antimicrobial Agents
lung
Answers Centers
prospects
rates
Suspected
disinfectant
WHO guideline
Mechanisms
whole genome sequencing
Cytokine-Targeted Therapy
investigational monoclonal antibody therapy bamlanivimab
health services
deadly immune reaction
mechanisms
International License
cross-species analyses
increased risk
unfavorable outcomes
Pfizer–BioNTech
respiratory system
blood vessel damage
Occurrence
Viral neutralization
European multinational study
foods10020283
accessory proteins
fetal growth restriction
interim names
healthcare
preventive measures such
normal immune responses
undetectable levels
Characteristics
cardiac muscle cell necrosis[128
Disinformation
GM‑CSF
adaptive immune response
MERS-CoV.
various stages
lopinavir
2nd U.S. Case
Health
GLOBAL HEALTH
issues such
fatalities
tertiary hospitals
possible treatments
Single-Center Case Series
U07.2
public health
flu remedies
Global Health
bamlanivimab
lactate dehydrogenase
Interim Guidelines
angiotensin
conditional recommendation
monoclonal antibodies
headache,[40
disinformation
experimental drug
index case
potential exposure
medical care
primary treatment
ischaemic events
World Health Organization
efficacious treatment
crisis management research
samples
infected person.[57
Molecular Medicine
medical help
antibodies specific
FDA
tissue samples
Too Much Hygiene
etesevimab
NSAIDs
multicentre cohort study
OCLC
true severity
EClinicalMedicine
Embarazo
NHS
suppression
U07.1
IFR
therapeutics
corona crisis
systemic corticosteroids
viable therapeutic option
longest survival times
autopsies
genetic variants
basis
care
RNA
prevention measures
Public Health
Preventive measures
multiple organ
Taste Disorders
combination
SARS-CoV-2 last
Lineage P.1
Pharmacological Sciences
ideal
WikispeciesTravel
Detection
pneumocyte hyperplasia
Spanish flu
pre-existing COPD
Interim Recommendations
Johns Hopkins Medicine
Multi-year studies
active clinical trials
previous kidney problems.[93
Laboratory testing
elevated IL‑2
acute myocardial injuries
Treatment guidelines
several places
worse prognosis
Convalescent plasma
drug use
day care
scrutiny
Macroscopy
Cause
authorised substances
sex-related data
National Health Service
endothelial cells
7917.ES.2020.25.32.2001410
More Evidence
rectal epithelium[82
inappropriate cleaning products
descriptive study
lesser prevalence
List
transmission potential
hospital
tid/119324
other types
Disease Burden
airborne transmission
Further information
blood clots.[237][238][239][240
spread rate
several other countries
WHO-recommended handrub formulations
Food safety
Q84263196
chronic kidney
ACE2 receptors
Australian Health Department.[17][18
pandemic.[385
Pregnancy
radiology
Covid Crisis
WikibooksQuotations
SARS-CoV-2.[222
severe asthma
World Health Organization Best Practices
current cases
Hospitalization Rates
vulnerability
Pronunciation
epithelial cells
poor prognosis
greater risk
spread
later stages
cm.v51i2.4266
C.D.C.
GND
Evaluation
guideline
cross sectional analysis
Pregnancy response
cb17874453
ACE inhibitors
Significant Community-Based Transmission
Variant
Evidence
blood vessel permeability
Guidelines
guidelines
respirators
Healthy diet
children
symptomatic people
Oxford–AstraZeneca
radiol.2020200642
IL‑7
emergency
alveolar damage
gamma-induced protein
Bilateral multilobar ground-glass opacities
pandemic wave
perinatal mortality
Other animals
mortality
vasopeptidase
Systemic inflammation
academic groups
Intensive care unit
antibody
acute myocardial injury
limited evidence
imaging
cardiovascular system
convalescent plasma therapy
keyboards
cardiovascular system.[84
neuroinflammation
atrial fibrillation
IL-1
microglia
common clusters
onset
intensive care unit
remote controls
CNS
solutions
vaccine availability improved.[145
Total deaths
Several laboratories
bat SARS-CoV
Blood vessel dysfunction
Physiological responses
FACTS
MIP‑1‑alpha
Phylogenetics
j.ssci.2020.104834
real-time reverse transcription polymerase chain reaction
sanitary crisis
vast spectrum
testing
sinuses
doses
mortality rate
Imaging Findings
Mortality
Children
ccdcw2020.032
heart inflammation
Kidney Damage
transcription-mediated amplification
human transmission
IFRs
antibody therapeutics
countries
Drug treatments
psychologic effects
genetic screen
Clinical Chemistry
asymptomatic people
people
infected white blood cell.[77
WiktionaryTextbooks
Tedros
infarction[128
associated mortality
global death-to-case ratio
First Global Patient Safety Challenge Clean Care
S2CID
tablets
Lymphocytic
other strains.[70
animal origin,[59
Greater prevalence
reduced lung function
Lung findings
neurotoxicity
U07.2MeSH
rspa.1927.0118
Translational Medicine
medical scientists
more severe responses
live-born children
Medical Internet Research
GISAID
accelerated research processes
bloodstream
See
Research
containment measures
Healthcare Products Regulatory Agency
PLOS Medicine
Immunity
researchers
electronic equipment
particles
fatality rates
case fatality rates
focus spike proteins expression
Herd immunity
international effort
IL-6
potential protective effect
CRP
findings
study.[231][232
D-dimer
infected.[348
Hypertension Research
Faulty Immune Response
test
Main article
NIH
first doses
vasoconstrictive responses
Implications
B.1.1.7
COPD
jmv.25992
hospital progress
young children
instance
Aggressive Non-Hodgkin Lymphoma
CFR
Medicine
exposure
Taşkın
SARS cases
High-Risk Groups
accelerated development
periods
poor outcomes
outbreak.[155
treatment
transmissions
Neurologic manifestations
j.jcv.2020.104371
underdeveloped countries such
Evidence-Based Medicine
tests
Several testing methods
median delay
masks
genes
Bibcode:2020CSFX
National Health Commission
fphys.2020.625110
common areas
common cause
emergency use authorization
Creative Commons Attribution
7–12 days
Severe Damage
Clinica Chimica Acta
Modelling research
estimates
Roche drug
science.abc3517
research data
identification
Multiple countries
glandular cells
global access
Early Transmission Dynamics
leukocytic infiltration
higher mortality rate
Genetic mechanisms
Scientific consensus
people[271
Global Impacts
blood-brain barrier
V130.Suppl_1.1547.1547
several days
victims
Directories
ACS Chemical Neuroscience
hospitalisation
studies
mortality rates
Kuksin
Languages
supplemental oxygen therapy.[403][404
global megatrial
bacterial spores
ongoing research
MCP1
Fever
Airborne transmission
Desigualdades preexistentes
ACE2 activators
j.metabol.2021.154753
Health Foundation
disease.[307
TNF‑α
s41423
genetic load
case fatality rate
Postmortem Findings
Face masks
Treatment Guidelines
pharmacy trade
Months
Small droplets
Sciences
expiratory droplets
Correlation
fatality
ICU.[209][210
metres
LDH
M20
interferon-gamma
miscarriage
scan
cyclical bouts
scenarios
same N501Y mutation
smell[41
Systematic review
systematic review
French hospital
potential intermediate animal host
higher mortality
actual mortality rate
Several notable variants
Guillain-Barré Syndrome
percent povidone-iodine
passive antibody therapy
Pharmacology
pulmonary circulation
WHO team
IL-6R
BMC Medicine
general behaviour
super-spreading events
guidance
Early reviews
earliest onset
severe impacts
membrane glycoprotein
recovery
pregnancy
Many factors
testing"[117
Exuberant Plasmocytosis
IDR.S258639
many types
Hand Hygiene
pharmacy settings
Bibcode:2020Natur.587
comorbidity
systemic inflammatory response
high D-dimer levels
Treatment
special surface glycoprotein
most countries
Main articles
s2213
Immunology
nucleocapsid proteins
different mortality rates
j.ejim.2020.04.037
older children
rate
Studies
high risk
results
gene target
vulnerable group
doi:10.7759
locations due
Frequency
Many countries
1449.e1
enough high-quality evidence
ACR Recommendations
case
pivotal link
government organisations
devices
Pathology
cma.j.issn.0254
Biomedical Science
high-quality healthcare.[156
aerosols
WHO.[277
phagocytosis
metaregression estimate
hospital treatment
ill persons
Incidence
types
NHS Improvement
protection
events such
healthy diet
most deaths
Preliminary Results
acute kidney injury
Health Research
major organs
milder responses
numbers
viral component
organizations worldwide.[386][387
higher risk
j.clim.2020.108427
organs
groups
current evidence
plasmocytosis
Efficacy
vasodilation
immune response.[98
several objectives
multiple admissions
Systematic Review
other areas
whole genome level
Several other articles
breathing difficulties
Food Industry
best,[392][393
Meta-Analysis
IP‑10
several smaller research papers
Headache
receptor-binding domain
auto-antibodies
scans
Other forms
experimental measures
Behaviors
BNF
Indirect Transmission
Pregnant women
Extracorporeal membrane oxygenation
Foti
U.S.
Mortality Frequency Measures
Therapeutics
Effectiveness
study
Ethnic Health Disparities
WikiquoteSource texts
many countries
subexponential growth
China CDC Weekly
clusters
U.S. Centers
Respiratory
many unknowns
death.[197][198][199
Intensive Care Medicine
intermediary wildlife host.[321][322
RAAS
enterocytes
infusion
article
Imaging
Wikimedia Commons
Wuhan Central Hospital
interleukin
Meta-analysis
Healthcare professionals
Health Care
examples
tocilizumab
available treatment
日本語
Emergency Use Authorization
Face coverings
possibility
Poor hygienic conditions
original SARS-CoV.[61
official case
protein
Long
standard methods
acute phase
NEJMcp2009249
~0.9%,[284
treatment options
IL-2
Human angiotensin
intrauterine growth restriction.[247
local inflammation
Wikiversity
Genetics
j.jmii.2020.02.012
Belgium
Safe Spaces
host receptor
shortness
greater risks
measures
fluids
Sex differences
upper respiratory tract
standard diagnostic method
nasal congestion
AJR.20.22954
CD013574
Covaxin
germs
estimation
BNC
familial cluster
epidemiologists
host factor
current patients.[418
oxygen
Characteristic imaging features
link
Potential Airborne Transmission
habits
days
early superspreading event
dexamethasone treatment
key metric
containment
Current evidence
bright regions
Later reviews
serological tests
research development
S2213
food industry
fimmu.2020.01648
Pediatric Healthcare Providers
certification
public health planning
Physiology
initial results
Demonstration
ACE2 cell surfaces
series
necessities
doi:10.1002/14651858.CD013574
response
injury
most situations
PCR
different age groups
alveolar cells
blood clots
j.ijid.2020.09.1464
formulations
coverings
available evidence
vasodilators
age groups
jmv.25731
transmission.[184][185
Various sources
s41591
manageable levels
Concern
Nature Microbiology
range
nucleic acid
nucleocapsid protein
j.ebiom.2020.102960
j.ajem.2020.04.048
health workers
nose
Evolution
Small droplet aerosols
lower respiratory tract
disease.[165
Science News
touch screens
peds.2020
randomised RECOVERY Trial
first detailed studies
Autopsies
CEBM
jmv.25889
DLCO
Drug Administration
Mortality rates
motor functions).[242][243
Hegde
other animals
sex differences
disease.[56
Pagni
other domesticated animals
cytokine storms
j.micinf.2020.05.002
Host
Curlie
Extracorporeal Membrane Oxygenation
restrictions
Control
Measures
European study
modes
Community Facilities
healthcare provider
Vabret
Perspectives
lipoic acid
aggravation
Early reports
Pharmaceutical Analysis
Scarce Medical Resources
International Concern.[348
Emergency Use
assurance
multiorgan dysfunction).[46
disease.[15
effectiveness
Prophylactic tocilizumab
References
Contents
NHS staff
remdesivir.[394
Official publications
Genetic analysis
asymmetric peripheral ground-glass opacities
uniform ratio
selection
chromosomal region
harmful.[187][203][204
MERS
Many groups
lungs
S2214
NEJMc2009191
Safer Care
offices
Cardiovascular Magnetic Resonance Imaging
advances
Risk
Proportion
known case
answers
Drug Resistance
caution
limited specificity
health-care workers
persons
EEA
zooanthroponosis
thrombosis
vents
pregnant women
hACE2
hypercoagulable state
Hydroxychloroquine
lung involvement
Potential
greater amounts
meta-analysis
sales
s0140
control
IJEBR-04
necessity
EpiVacCorona
development
Sanità
conditions.[309
NEJMc2036242
human-to-human
fetal death
S-protein
face masks
Creative Commons Attribution-ShareAlike License
fomites
CoronaVac
jmv.25707
Contributions
S2468
impact
early stages
Bibcode:2017Sci
showvte
U.S. Food
gastrointestinal organs
Coombs
public use
subsequent damage
number
company CapitalBio Medlab
Testing
Proper hand hygiene
doi:10.1080/21645515.2020.1735227
Thrombosis
lung surfactants
d41586
posterior distribution
Results
improvement
s41586
loss
Monoclonal Antibody
valves
Bibcode:1927RSPSA.115
population characteristics such
prisons due
significant number
ECMO
personal protective equipment
alcohol-based hand sanitiser
Recovery trial
Drug Development Research
health insurance
j.cca.2020.06.045
NHS England
severe course
First-of-its-kind African trial
Immune responses
cumulative total
Inquiry
headache
Solidarity trial
early use
Pediatrics
low levels
ECDC
poor access
inadequate ventilation.[20
alveolar cavities
serum ferritin blood test
eid2608.200679
overview
External links
NIH Themed Review
RFI
availability
receptor usage
weeks
appearance
s41569
blood vessels
nejmc2033369
safety concerns
Wuhan doctor
S0140
Morbidity
Mujeres mayores
Tropical Medicine
Respiratory function
presentation
scientists
olfactory
great ape species such
Coding
disease.[113
50–100 percent isopropanol
Other candidates
medical charts
healthcare workers
association
European Medicines Agency
Hidden Menace
Impact
prone positioning
doi:10.1038/
corona
health chief
March-August
longer life expectancy
BLT.20.253591
j.pulmoe.2020.10.013
weeks gestation
damage
solidarity trial
implementation
acute cardiac injury
Other people
Spread
Tissue Distribution
fluid therapy
Exaggerated risk
Outcomes
metric
host cells
Vaccine Centre
humans
Loss
good evidence
unknown cause
genomic diversity
cells specific
Processing Specimens
j.jhin.2020.09.022
age specificity
word
sale
exhalation valve
insufficient evidence
highest risk
UTC
clinical trial.[137][138
Coagulation
People
monocytic infiltration
Massachusetts Medical Society
second doses
Deutsch
regions
arXiv:2005.04007
astrocytes
official reports
doctors
Leukoerythroblastic reaction
Macrophages
organisation
cells
Overview
Antibody
such developments
Whole World
Seminati
jamainternmed.2020.1856
other cats
autopsy.[94
hydroxychloroquine
WikisourceLearning resources
Duration
DNA analysis
years
high levels
genders.[293][294
WikiversityData
Patiño-Lugo
lives
technical guidance
large study
heart failure
admission
supplemental oxygen